Interdisciplinary Melanoma Cooperative Group Translational Research Fellowship

We are not currently accepting applications for the 2015-2016 academic year.

For many years, the Ronald O. Perelman Department of Dermatology maintained a one-year, non-accredited clinical fellowship in melanoma under the supervision of Dr. Alfred Kopf, who has recently retired. Many of his trainees have become prominent melanoma clinicians at the local, national and international levels. The current fellowship is a 2-year position that has the goal of training clinicians in the methodology of translational research as applied to melanoma. Fellowship candidates are typically MD’s who have completed a medical internship and are seeking to enhance their chances of matching for a dermatology residency. We have had five fellows over the last eight years who have matched in dermatology programs here at NYU or at other competitive institutions.

Translational Research is defined by the NIH as “…research conducted with human subjects (or on material of human origin such as tissues, specimens, and cognitive phenomena) for which investigators interact directly with human subjects. This area of research includes: development of new technologies, mechanisms of human disease, therapeutic interventions, and clinical trials.” Our fellows obtain an in-depth and broad experience in melanoma translational research by interacting with patients, clinicians and laboratory investigators.

Research Training

Under the mentorship of Dr. Iman Osman, the fellow will assist in ongoing research projects and is expected to develop at least one project that they will lead as first author. The fellow will become completely familiar with the NYU Interdisciplinary Melanoma Cooperative Group (IMCG) research program and will assist in the supervision of the data managers who maintain the clinical/pathological database. The fellow may assist in the enrollment of patients into the IMCG database, but this will not be a primary responsibility.

By the end of the fellowship, the trainee will have gained knowledge and experience in translational research in melanoma. They will have an in-depth understanding of issues involving testing associations between basic science data and clinical variables. Specifically, fellows will learn to: 1) design studies addressing a translational research question; 2) determine relevant statistical issues for a particular study; 3) define relevant clinical information to be linked to basic science data.

Clinical Training

The main clinical experience for the fellow is working in the Pigmented Lesion Clinic rotating with Drs. David Polsky and Jennifer Stein one half-day per week. The Pigmented Lesion Clinic is utilized by patients at high risk for developing melanoma, either due to personal or family history of melanoma or possession of significant clinical risk factors for melanoma (i.e. increased number of moles or presence of atypical moles). The fellow may also observe general dermatology clinical sessions with other dermatology attendings and in the practices of Drs. Russell Berman and Richard Shapiro in Surgical Oncology and Dr. Anna Pavlick in Medical Oncology. These observing experiences will broaden their education and perspective concerning the care of melanoma patients.

In the clinic, the fellow’s role is strictly that of an observer, similar to a medical student. They have no primary patient care responsibilities. The fellow may record patient history, but the remainder of patient encounters will be as an observer of the attending physician. They will assist with documentation and minor procedures, the imaging of skin lesions, and patient education, among other responsibilities. The fellow may occasionally contact patients by telephone to discuss benign skin biopsy results or to facilitate the review of outside medical records and skin biopsies.

Contact

Please send a letter of interest and curriculum vitae to:
Elise Kelman, Associate Director of Research Administration
The Ronald O. Perelman Department of Dermatology
NYU Langone Medical Center
Cutaneous Biology Program
522 1st Avenue, Smilow Room 401
New York, NY 10016
Telephone: (212) 263-5070
Fax: (212) 263-5819

Email: Elise.Kelman@nyumc.org

Publications of Recent Trainees

1. Velazquez EF, Yancovitz M, Pavlick A, Berman R, Shapiro R, Bogunovic D, O'Neill D, Yu YL, Spira J, Christos PJ, Zhou XK, Mazumdar M, Nanus DM, Liebes L, Bhardwaj N, Polsky D, Osman I. Clinical relevance of Neutral Endopeptidase (NEP/CD10) in melanoma. J Transl Med. 2007 Jan 5; 5:2.

2. Yancovitz M, Yoon J, Mikhail M, Gai W, Shapiro R, Berman R, Pavlick A, Osman I, Polsky D. Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. J Mol Diag. 2007 Apr; 9(2):178-83.

3. Yancovitz M, Finelt N, Warycha M, Christos P, Mazumdar M, Shapiro R, Pavlick A, Osman I, Polsky D, Berman R. Role of Radiologic Imaging at Time of Initial Diagnosis of Stage T1b-T3b Melanoma. Cancer. 2007 Jul 9; 110(5):1107-14.

4. Velazquez EF, Jungbluth AA, Yancovitz M, Gnjatic S, Adams S, O'neill D, Zavilevich K, Albukh T, Christos P, Mazumdar M, Pavlick A, Polsky D, Shapiro R, Berman R, Spira J, Busam K, Osman I, Bhardwaj N. Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM) - correlation with prognostic factors. Cancer Immun. 2007 Jul 12; 7:11.

5. Abassi NR, Yancovitz M, Gutkowicz-Krusin D, Panageas KS, Mihm MC, Googe P, King R, Prieto V, Osman I, Friedman RJ, Rigel DS, Kopf AW, Polsky D. Utility of lesion diameter in the clinical diagnosis of cutaneous melanoma. Arch Dermatol. 2008;144:469-474.

6. Han SY, Gai W, Yancovitz M, Osman I, Di Como CJ, Polsky D. Nucleofection is a highly effective gene transfer technique for human melanoma cell lines. Exp Dermatol. 2008 May; 17(5):405-11. Epub 2008 Feb 27.

7. Detection of BRAF mutations in plasma and tissues of patients with metastatic melanomaM Yancovitz, J Yoon, M Warycha, JA Zakrzewski, J Spira, JZ Yu, W Gai, RL Shapiro, RS Berman, AC Pavlick, S Meehan, H Kamino, F Darvishian, I Osman, D Polsky. International Melanoma Congress, New York, NY Nov 30-June 3, 2007

8. Detection of BRAF kinase mutations in melanoma, ovarian and prostate carcinomas - Evidence for tumor heterogeneity in clinical samples. AJ Litterman, M Yancovitz, R Shapiro, R Berman, A Pavlick, F Darvishian, S Blank, P Lee, I Osman, D Polsky. Accepted to the ASCO 2009 Annual Meeting, Poster Discussion.

9. Friedman RJ, Gutkowicz-Krusin D, Farber MJ, Warycha M, Schneider-Kels L, Papastathis N, Mihm Jr MC, Googe P, King R, Prieto VG, Kopf AW, Polsky D, Rabinovitz H, Oliviero M, Cognetta A, Rigel DS, Marghoob A, Rivers J, Johr R, Grant-Kels JM, Tsao H. The diagnostic performance of expert dermoscopists vs a computer-vision system on small-diameter melanomas. Arch Dermatol 2008;144:476-482.

10. Ng B, Zakrzewski J, Warycha M, Christos PJ, Shapiro RL, Berman RS, Pavlick AC, Polsky D, Mazumdar M, Montgomery A, Liebes L, Brooks PC, Osman I. Shedding of distinct cryptic collagen epitope (HU177) in sera of melanoma patients. Clin Cancer Res. 2008 Oct 1; 14(19):6253.

11. Warycha MA, Christos PJ, Mazumdar M, Darvishian F, Shapiro RL, Berman RS, Pavlick AC, Kopf AW, Polsky D, Osman I. Changes in the presentation of nodular and superficial spreading melanomas over 35 years.Cancer. 2008 Dec 15; 113(12):3341-8.

12. Yu JZ, Warycha MA, Christos PJ, Darvishian F, Yee H, Buckley MT, Liebes LF, Pavlick AC, Polsky D, Brooks PC, Osman I. Assessing the clinical utility of measuring Insulin-like Growth Factor Binding Proteins in tissues and sera of melanoma patients. J Transl Med. 2008 Nov 24; 6(1):70.

13. Warycha MA, Zakrzewski J, Ni O, Shapiro RL, Berman RS, Pavlick AC, Polsky D, Mazumdar M, Osman I. Meta-Analysis of Sentinel Lymph Node Positivity in Thin Melanoma (≤ 1mm). Cancer. 2009 Feb 15; 115(4):869-79.

14. Firoz EF, Warycha M, Zakrzewski J, Pollens D, Wang G, Shapiro R, Berman R, Pavlick A, Manga P, Ostrer H, Celebi JT, Kamino H, Darvishian F, Rolnitzky L, Goldberg JD, Osman I, Polsky D. Association of MDM2SNP309 and Melanoma Onset in Women. Clin Cancer Res. 2009 Apr 1; 15(7):2573-80. Epub 2009 Mar 24.

15. O’Reilly K, Warycha M, Roderick V, Davies M, Zhou K, Yee H, Bhardwaj N, Pavlick AC, Mills G, Rosen N, Osman I. 4E-BP1: A Node of RAS/MAPK and PI3K/AKT Pathway Crosstalk in Metastatic Melanoma. Clin Cancer Res. 2009 Apr 15; 15(8):2872-8. Epub 2009 Mar 31.

16. Differential expression of Insulin-like Growth Factor Binding Protein-4 (IGFBP-4) and Integrinavb3 in melanoma progression. JZ Yu, M Warycha, J Zakrzewski, H Yee, P Christos, R Berman, A Pavlick, R Shapiro, H Kamino, L Liebes, P Brooks, I Osman. International Melanoma Congress, New York, NY Nov 30-June 3, 2007

17. Detection of BRAF mutations in plasma and tissues of patients with metastatic melanomaM Yancovitz, J Yoon, M Warycha, JA Zakrzewski, J Spira, JZ Yu, W Gai, RL Shapiro, RS Berman, AC Pavlick, S Meehan, H Kamino, F Darvishian, I Osman, D Polsky. International Melanoma Congress, New York, NY Nov 30-June 3, 2007

18. 4EBP1: A Node of Pathway Crosstalk in Metastatic Melanoma. K O'Reilly, M Warycha, M Davies, X Zhou, H Yee, N Bhardwaj, A Pavlick, G Mills, N Rosen, I Osman. ASCO Annual Meeting in Chicago, IL May 30-June 3, 2008: Poster Discussion.

19. MDM2 SNP309 and Melanoma Risk among Women. EF Firoz, M Warycha, R Shapiro, R Berman, H Kamino, F Darvishian, L Rolnitzky, J Goldberg, I Osman, D Polsky. ASCO Annual Meeting in Chicago, IL May 30-June 3, 2008: General Poster session.

20. Different clinical behavior of nodular melanoma (NM) compared to superficial spreading melanoma (SSM) at New York University from 1972 to present. MA Warycha, JZ Yu, P Christos, F Darvishian, H Kamino, R Shapiro, R Berman, AW Kopf, D Polsky, I Osman. J Clin Oncol 26: 2008 (May 20 suppl; abstr 20001).

21. Meta-Analysis of Sentinel Lymph Node Positivity in Thin Melanoma (≤ 1mm). J Zakrzewski, MA Warycha, Q Ni, R Shapiro, R Berman, A Pavlick, D Polsky, M Mazumda, I Osman. Proceedings of ASCO 2008 Annual Meeting. J Clin Oncol 26: 2008 (May 20 suppl; abstr 20032).

22. Tumor Heterogeneity: Evidence from BRAF V600E mutation detection. A Litterman, D Pollens, M Warycha, R Shapiro, R Berman, A Pavlick, S Blank, P Lee, I Osman, D Polsky. Proceedings of ASCO 2008 Annual Meeting. J Clin Oncol 26: 2008 (May 20 suppl; abstr 20022).

23. Wich LG, Hamilton HK, Shapiro RL, Pavlick AC, Berman RS, Polsky D, Goldberg JD, Hernando E, Manga P, Krogsgaard M, Kamino H, Darvishian F, Lee P, Orlow SJ, Ostrer H, Bhardwaj N, Osman I. Development of a Multidisciplinary Prospective Clinicopathological-Biospecimen Repository to Advance Translational Research in Melanoma. Am J Transl Res. 2009; 1(1):35-43.

24. The Development of a Multidisciplinary Prospective Clinicopathological-Biospecimen Repository to Advance Translational Research in MelanomaHK Hamilton, LG Wich, D Polsky, SJ Orlow, I Osman. 2nd Annual World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers in Clearwater, FL. Nov 20-21, 2008.

25. Chen M, Rose AE, Osman I, Orlow SJ. Celastrol Synergistically Enhances Temozolomide Cytotoxicity in Melanoma Cells. Mol Cancer Res. 2009 Dec; 7(12):1946-53. Epub 2009 Nov. 24.

26. Hamilton, HK, Rose AE, Christos PJ, Shapiro RL, Berman RS, Mazumdar M, Ma MW, Krich D, Liebes L, Brooks PC, Osman I. Increased shedding of hu177 correlates with worse prognosis in primary melanoma. J Transl Med. 2010 Feb23;8:19.

27. Segura, MF, Belitskaya-Levy I, Rose AEZakrzewski J, Gaziel A, Hanniford D, Darvishian F, Berman RS, Shapiro RL, Pavlick AC, Osman I, Hernando E. Melanoma microrna signature predicts post-recurrence survival.Clin Cancer Res. 2010 Mar1;16(5):1577-86.

28. Rose AE, Wang G, Hanniford D, Monni S, Tu T, Shapiro RL, Berman RS, Pavlick AC, Pagano M, Darvishian F, Mazumdar M, Hernando E, Osman I. Clinical relevance of SKP2 alterations in metastatic melanoma. Pigment Cell Melanoma Res. 2010 Sep 30.

29. Zakrzewski J, Geraghty LN, Rose AE, Christos P, Mazumdar M, Krich D, Polsky D, Shapiro R, Berman R, Darvishian F, Pavlick A, Osman I. Predictors of survival in melanoma patients with brain metastases. Cancer. 2010 Nov 8.

30. Rose AE, Poliseno L, Wang J, Clark M, Pearlman A, Wang G, Vega Y Saenz de Miera EC, Medicherla R, Christos PJ, Shapiro RL, Pavlick AC, Darvishian F, Zavadil J, Polsky D, Hernando E, Ostrer H, Osman I. Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression.Cancer Res. 2011 Feb 22.

31. Ma MW*, Tu TJ*, Monni S, Rose AE, Yee H, Darvishian F, Polsky D, Berman RS, Shapiro RL, Pavlick AC, Mazumdar M, Osman I. A High Proliferative Index of Recurrent Melanoma Is Associated with Worse Survival.Oncology. 2011 Jun 24;80(3-4):181-187. (* Co-First Author)

32. Ma MW*, Wich LG*, Price LS, Sidash S, Berman RS, Pavlick AC, Miller G, Sarpel U, Goldberg JD, Osman I. Impact of socioeconomic status and sociodemographic factors on melanoma presentation among non-white patients. Journal Community Health. 2011 Jun;36(3):461-8.          (* Co-First Author)

33. Rose AE, Christos PJ, Lackaye D, Shapiro RL, Berman RS, Mazumdar M, Kamino H, Osman I, Darvishian F. Clinical relevance of detection of lymphovascular invasion in primary melanoma using endothelial markers D2-40 and CD34. Am J Surg Pathol. 2011 Oct;35(10):1441-9.

34. Primary melanoma features associated with increased risk of brain metastasisMa MW, Qian M, Lackaye D, Berman RS, Shapiro RL, Pavlick AC, Golfinos J, Parker E, Hernando E, Shao Y, Osman I. Proceedings of ASCO 2011 Annual Meeting. J Clin Oncol 29:15s, 2011(suppl; abstr 8560).

35. An analysis of altered melanoma matrix metalloproteinase-23 (MMP-23) expression and response to immune biologic therapy. Krogsgaard M, Ma MW, Friedman EB, Vega-Saenz de Miera E, Darvishian F, Perez-Garcia A, Berman RS, Shapiro RL, Christos PJ, Osman I, Pavlick AC. Proceedings of ASCO 2011 Annual Meeting. J Clin Oncol 29:15s, 2011 (suppl; abstr 8541).

36. Impact of immune modulation on sentinel lymph node positivity and outcome in melanoma patients.Medicherla RC, Ma MW, Qian M, Vega-Saenz de Miera E, Berman RS, Shapiro RL, Pavlick AC, Bhardwaj N, Shao Y, Osman I, Darvishian F. Proceedings of ASCO 2011 Annual Meeting. J Clin Oncol 29:15s, 2011 (suppl; abstr 8561).

37. The prognostic relevance of altered antiglycan antibody profiles in the sera of primary melanoma patients.Haimovic A, Ma MW, Vuskovic MI, Miller T, DiBenedetto M, Grossman J, Shapiro RL, Pavlick AC, Berman RS, Pass HI, Huflejt M, Osman I. Proceedings of ASCO 2011 Annual Meeting. J Clin Oncol 29:15s, 2011 (suppl; abstr 8562).

38. An Analysis of sera-based microRNAs as biomarkers of recurrence in melanoma. Friedman EB, Shang S, Vega-Saenz de Miera E, Ma MW, Berman RS, Shapiro RL, Pavlick AC, Hernando E, Shao Y, Osman I. Proceedings of ASCO 2011 Annual Meeting. J Clin Oncol 29:15s, 2011   (suppl; abstr 8513).

39. Hwa C, Price LS, Belitskaya-Levy I, Ma MW, Shapiro RL, Berman RS, Kamino H, Darvishian F, Osman I, Stein JA. Single versus Multiple Primary Melanomas: Old Questions and New Answers. Cancer. 2012 Jan 13.

40. Ma MW, Medicherla RC, Qian M, Vega-Saenz de Miera E, Friedman EB, Berman RS, Shapiro RL, Pavlick AC, Ott PA, Bhardwaj N, Shao Y, Osman I, Darvishian F. Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node.   Mod Pathol. 2012 Mar 16.

41. Ma MW, Qian M, Lackaye DJ, Berman RS, Shapiro RL, Pavlick AC, Golfinos JG, Parker EC, Darvishian F, Hernando E, Shao Y and Osman I. Challenging the current paradigm of melanoma progression: brain metastasis as isolated first visceral site. Neuro-Oncology. 2012 Jul;14(7):849-58.

42. Friedman EB, Shang S, Vega-Saenz de Miera E, Fog JU, Teilum MW, Ma MW, Berman RS, Shapiro RL, Pavlick AC, Hernando E, Baker A, Shao Y and Osman I. Serum microRNAs as prognostic biomarkers for recurrence in melanoma. J Transl Med. 2012 Aug 2;10:155.

43. MicroRNA alterations associated with BRAF status in melanoma. MW Ma, JA Farhadian, EB Friedman, E Vega-Saenz de Miera, D Hanniford, MF Segura, RS Berman, RL Shapiro, AC Pavlick, J Zavadil, E Hernando, I Osman. Proceedings of ASCO 2012 Annual Meeting. J Clin Oncol 30,2012(suppl;abstr 8565).

44. The melanoma risk loci as determinants of melanoma prognosis. J Rendleman, S Shang, C Brocia, MW Ma,R Shapiro, R Berman, A Pavlick, Y Shao, I Osman, T Kirchhoff. Proceedings of ASCO 2012 Annual Meeting. J Clin Oncol 30, 2012(suppl; abstr 8557).

45. Prognostic value of mitosis-specific antibodies and computer image analysis in calculating mitotic rate in melanoma. C Hale, M Qian, MW Ma, Y Shao, D Polsky, RL Shapiro, RS Berman, AC Pavlick, I Osman, F Darvishian. Proceedings of ASCO 2012 Annual Meeting. J Clin Oncol 30, 2012(suppl; abstr el9003).

46. TILs in Metastatic Melanoma Tumors: A Biomarker for Immunotherapy? S Chandra, Y Ding, MW Ma, M Bannan, F Darvishian, R Berman, R Shapiro, M Krogsgaard, I Osman, AC Pavlick. Proceedings of ASCO 2012 Annual Meeting. J Clin Oncol 30, 2012(suppl; abstr 8589).